Acumapimod (BCT197)

For the potential treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).  Acumapimod is an oral p38 MAP kinase inhibitor that has completed Phase 2 development as first-line therapy for severe acute exacerbations of AECOPD. Acumapimod is given during a severe exacerbation to reduce the risk of further exacerbations.
STATUS: Open-to-Partnership